# Allergy and COVID-19 Vaccines

> **NCT05028257** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 117 (actual)

## Conditions studied

- Anaphylactic Reaction
- Vaccine Reaction

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccines

## Key facts

- **NCT ID:** NCT05028257
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-15
- **Primary completion:** 2023-05-22
- **Final completion:** 2023-05-22
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028257, "Allergy and COVID-19 Vaccines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05028257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*